| Description |
A cell-permeable thiadiazolyloxybutanol compound that inhibits epithelial-mesenchymal transition-(EMT) dependent cancer proliferation (% viability by MTT = 2.7%/RPMI-8226, 12%/MCF7, 15%/WM266, 32%/SK-Mel-28, 44%/WM115, 63%/SW480 vs. 80%/normal fibroblast; 5 µM C19 for 96 h) due to autophagy, but not apoptosis, induction by blocking both basal & ligands-stimulated Hippo, Wnt, and TGF-β pathway signalings (IC 50 <2.5 µM in 293-based reporter assays; 24 h treatment) via simultaneous AMPK, Lats1 & Mst1 activation/phosphorylation induction (Effective conc <5 µM), resulting in downstream GSK-3β activation/dephosphorylation and GSK-3β destruction complex-mediated Hippo pathway transducer TAZ degradation
|